Case W Mcnamara

List of Publications by Year
in descending order

53 papers	5,038 citations	159585 30 h-index	168389 53 g-index
53 all docs	53 docs citations	53 times ranked	6105 citing authors

#	Article	IF	Citations
1	Spiroindolones, a Potent Compound Class for the Treatment of Malaria. Science, 2010, 329, 1175-1180.	12.6	1,031
2	In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9059-9064.	7.1	400
3	Targeting Plasmodium PI(4)K to eliminate malaria. Nature, 2013, 504, 248-253.	27.8	377
4	Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery. Science, 2011, 334, 1372-1377.	12.6	308
5	Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. Nature Chemical Biology, 2008, 4, 347-356.	8.0	203
6	Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite Cladosporin. Cell Host and Microbe, 2012, 11, 654-663.	11.0	202
7	Mitotic Evolution of Plasmodium falciparum Shows a Stable Core Genome but Recombination in Antigen Families. PLoS Genetics, 2013, 9, e1003293.	3.5	192
8	Na+ Regulation in the Malaria Parasite Plasmodium falciparum Involves the Cation ATPase PfATP4 and Is a Target of the Spiroindolone Antimalarials. Cell Host and Microbe, 2013, 13, 227-237.	11.0	185
9	The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10750-10755.	7.1	165
10	M1 Protein Allows Group A Streptococcal Survival in Phagocyte Extracellular Traps through Cathelicidin Inhibition. Journal of Innate Immunity, 2009, 1, 202-214.	3.8	157
11	Coiled-Coil Irregularities and Instabilities in Group A Streptococcus M1 Are Required for Virulence. Science, 2008, 319, 1405-1408.	12.6	137
12	Open-source discovery of chemical leads for next-generation chemoprotective antimalarials. Science, 2018, 362, .	12.6	99
13	Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7015-7020.	7.1	94
14	A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. PLoS Neglected Tropical Diseases, 2017, 11, e0005373.	3.0	91
15	Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 21486-21491.	7.1	89
16	A Chemical Genomic Analysis of Decoquinate, a Plasmodium falciparum Cytochrome b Inhibitor. ACS Chemical Biology, 2011, 6, 1214-1222.	3.4	84
17	High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria. ACS Infectious Diseases, 2016, 2, 281-293.	3.8	84
18	Cell-based screen for discovering lipopolysaccharide biogenesis inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6834-6839.	7.1	81

#	Article	IF	Citations
19	Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nature Communications, 2021, 12, 3309.	12.8	81
20	Mutations in the P-Type Cation-Transporter ATPase 4, PfATP4, Mediate Resistance to Both Aminopyrazole and Spiroindolone Antimalarials. ACS Chemical Biology, 2015, 10, 413-420.	3.4	75
21	KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage ParasitesIn Vitro. Antimicrobial Agents and Chemotherapy, 2014, 58, 1586-1595.	3.2	61
22	Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease. PLoS Pathogens, 2015, 11, e1005058.	4.7	52
23	MalDA, Accelerating Malaria Drug Discovery. Trends in Parasitology, 2021, 37, 493-507.	3.3	51
24	A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii. Nature Microbiology, 2020, 5, 1134-1143.	13.3	50
25	Inhibitors of Plasmodial Serine Hydroxymethyltransferase (SHMT): Cocrystal Structures of Pyrazolopyrans with Potent Blood- and Liver-Stage Activities. Journal of Medicinal Chemistry, 2015, 58, 3117-3130.	6.4	46
26	Bicyclic azetidines kill the diarrheal pathogen Cryptosporidium in mice by inhibiting parasite phenylalanyl-tRNA synthetase. Science Translational Medicine, 2020, 12, .	12.4	45
27	Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis. Nature Communications, 2019, 10, 2816.	12.8	43
28	Modular, stereocontrolled C _{Î²} â€“H/C _{Î±} â€“C activation of alkyl carboxylic acids. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8721-8727.	7.1	39
29	Discovery of short-course antiwolbachial quinazolines for elimination of filarial worm infections. Science Translational Medicine, 2019, 11, .	12.4	36
30	Boron-Pleuromutilins as Anti-Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis. Journal of Medicinal Chemistry, 2019, 62, 2521-2540.	6.4	35
31	Prioritization of Molecular Targets for Antimalarial Drug Discovery. ACS Infectious Diseases, 2021, 7, 2764-2776.	3.8	35
32	The Tuberculosis Drug Accelerator at year 10: what have we learned?. Nature Medicine, 2021, 27, 1333-1337.	30.7	32
33	Target identification and validation of novel antimalarials. Future Microbiology, 2011, 6, 693-704.	2.0	30
34	Lead Optimization of Imidazopyrazines: A New Class of Antimalarial with Activity on Plasmodium Liver Stages. ACS Medicinal Chemistry Letters, 2014, 5, 947-950.	2.8	30
35	Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis. International Journal for Parasitology, 2017, 47, 753-763.	3.1	30
36	Antimalarial Peptide and Polyketide Natural Products from the Fijian Marine Cyanobacterium Moorea producens. Marine Drugs, 2020, 18, 167.	4.6	29

#	Article	IF	Citations
37	A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors. Nature Communications, 2019, 10, 1862.	12.8	28
38	Peyssonnosides Aâ€“B, Unusual Diterpene Glycosides with a Sterically Encumbered Cyclopropane Motif: Structure Elucidation Using an Integrated Spectroscopic and Computational Workflow. Journal of Organic Chemistry, 2019, 84, 8531-8541.	3.2	26
39	Probing the Open Global Health Chemical Diversity Library for Multistage-Active Starting Points for Next-Generation Antimalarials. ACS Infectious Diseases, 2020, 6, 613-628.	3.8	26
40	Advances in Antiwolbachial Drug Discovery for Treatment of Parasitic Filarial Worm Infections. Tropical Medicine and Infectious Disease, 2019, 4, 108.	2.3	24
41	Antibacterial Oligomeric Polyphenols from the Green Alga Cladophora socialis. Journal of Organic Chemistry, 2019, 84, 5035-5045.	3.2	22
42	Phenotypic screening techniques forCryptosporidiumdrug discovery. Expert Opinion on Drug Discovery, 2021, 16, 59-74.	5.0	16
43	An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease. Pathogens, 2021, 10, 71.	2.8	16
44	Specificity and cooperativity at Î²â€lactamase position 104 in TEMâ€1/BLIP and SHVâ€1/BLIP interactions. Proteins: Structure, Function and Bioinformatics, 2011, 79, 1267-1276.	2.6	15
45	Iron limitation in M. tuberculosis has broad impact on central carbon metabolism. Communications Biology, 2022, 5, .	4.4	13
46	Herbicidins from Streptomyces sp. CB01388 Showing Anti-Cryptosporidium Activity. Journal of Natural Products, 2018, 81, 791-797.	3.0	12
47	Novel chemical starting points for drug discovery in leishmaniasis and Chagas disease. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 10, 58-68.	3.4	12
48	Hydrogen peroxide induces the dissociation of GroEL into monomers that can facilitate the reactivation of oxidatively inactivated rhodanese. International Journal of Biochemistry and Cell Biology, 2004, 36, 505-518.	2.8	11
49	Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis. PLoS Pathogens, 2022, 18, e1009862.	4.7	11
50	Short-course quinazoline drug treatments are effective in the Litomosoides sigmodontis and Brugia pahangi jird models. International Journal for Parasitology: Drugs and Drug Resistance, 2020, 12, 18-27.	3.4	10
51	Repurposing Infectious Disease Hits as Anti-Cryptosporidium Leads. ACS Infectious Diseases, 2021, 7, 1275-1282.	3.8	8
52	Discovery of Kirromycins with Anti-Wolbachia Activity from Streptomyces sp. CB00686. ACS Chemical Biology, 2019, 14, 1174-1182.	3.4	7
53	High-Content Screening for Cryptosporidium Drug Discovery. Methods in Molecular Biology, 2020, 2052, 303-317.	0.9	2